LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial

Aditya Bardia, Komal Jhaveri, S-A. Im, S. Pernas Simon, Michelino De Laurentiis, S. Wang, Noelia Martínez-Jáñez, Giuliano Santos Borges, David W. Cescon, Masaya Hattori, Yen‐Shen Lu, Erika Hamilton, Qilong Zhang, Junji Tsurutani, Kevin Kalinsky, Linhong Xu, Neelima Denduluri, Hope S. Rugo, Binghe Xu, Barbara Pistilli